Literature DB >> 17637389

Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.

Peter J Hoskin1, Dawn M Carnell, N Jane Taylor, Rowena E Smith, J James Stirling, Frances M Daley, Michele I Saunders, Søren M Bentzen, David J Collins, James A d'Arcy, Anwar P Padhani.   

Abstract

PURPOSE: To investigate the ability of blood oxygen level-dependent (BOLD) MRI to depict clinically significant prostate tumor hypoxia. METHODS AND MATERIALS: Thirty-three patients with prostate carcinoma undergoing radical prostatectomy were studied preoperatively, using gradient echo sequences without and with contrast medium enhancement, to map relative tissue oxygenation according to relaxivity rates and relative blood volume (rBV). Pimonidazole was administered preoperatively, and whole-mount sections of selected tumor-bearing slices were stained for pimonidazole fixation and tumor and nontumor localization. Histologic and imaging parameters were independently mapped onto patient prostate outlines. Using 5-mm grids, 861 nontumor grid locations were compared with 237 tumor grids (with >50% tumor per location) using contingency table analysis with respect to the ability of imaging to predict pimonidazole staining.
RESULTS: Twenty patients completed the imaging and histologic protocols. Pimonidazole staining was found in 33% of nontumor and in 70% of tumor grids. The sensitivity of the MR relaxivity parameter R(2)* in depicting tumor hypoxia was high (88%), improving with the addition of low rBV information (95%) without changing specificity (36% and 29%, respectively). High R(2)* increased the positive predictive value for hypoxia by 6% (70% to 76%); conversely, low R(2)* decreased the likelihood of hypoxia being present by 26% (70% to 44%) and by 41% (71% to 30%) when combined with rBV information.
CONCLUSION: R(2)* maps from BOLD-MRI have high sensitivity but low specificity for defining intraprostatic tumor hypoxia. This together with the negative predictive value of 70% when combined with blood volume information makes BOLD-MRI a potential noninvasive technique for mapping prostatic tumor hypoxia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637389     DOI: 10.1016/j.ijrobp.2007.01.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  61 in total

1.  Is T2* enough to assess oxygenation? Quantitative blood oxygen level-dependent analysis in brain tumor.

Authors:  Thomas Christen; Benjamin Lemasson; Nicolas Pannetier; Regine Farion; Chantal Remy; Greg Zaharchuk; Emmanuel L Barbier
Journal:  Radiology       Date:  2011-12-09       Impact factor: 11.105

2.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

3.  Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

Authors:  Susan L Dalrymple; Robyn E Becker; Haoming Zhou; Theodore L DeWeese; John T Isaacs
Journal:  Prostate       Date:  2011-08-11       Impact factor: 4.104

4.  AMP-activated protein kinase promotes human prostate cancer cell growth and survival.

Authors:  Hyeon Ung Park; Simeng Suy; Malika Danner; Vernon Dailey; Ying Zhang; Henghong Li; Daniel R Hyduke; Brian T Collins; Gregory Gagnon; Bhaskar Kallakury; Deepak Kumar; Milton L Brown; Albert Fornace; Anatoly Dritschilo; Sean P Collins
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

5.  In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation.

Authors:  Jian Cao; James Campbell; Li Liu; Ralph P Mason; Alexander R Lippert
Journal:  Anal Chem       Date:  2016-04-15       Impact factor: 6.986

6.  Blood oxygenation level-dependent MR imaging as a predictor of therapeutic response to concurrent chemoradiotherapy in cervical cancer: a preliminary experience.

Authors:  Chan Kyo Kim; Sung Yoon Park; Byung Kwan Park; Won Park; Seung Jae Huh
Journal:  Eur Radiol       Date:  2014-04-25       Impact factor: 5.315

7.  Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.

Authors:  Guangyu Wu; Guiqin Liu; Wen Kong; Jianxun Qu; Shiteng Suo; Xiaosheng Liu; Jianrong Xu; Jin Zhang
Journal:  Eur Radiol       Date:  2017-01-27       Impact factor: 5.315

Review 8.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 9.  Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.

Authors:  James P B O'Connor; Simon P Robinson; John C Waterton
Journal:  Br J Radiol       Date:  2019-01-24       Impact factor: 3.039

Review 10.  Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism.

Authors:  Masayuki Matsuo; Shingo Matsumoto; James B Mitchell; Murali C Krishna; Kevin Camphausen
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.